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The murine breast cancer cells (4T1) grown both in female BALB/c mice and in culture were treated with anastrozole (50µg/mL),
tamoxifen citrate (5µg/mL), and the combination of the two drugs in order to determine treatment eﬃcacies, toxic potential, and
the mechanism of cell death. The in vivo treatments were evaluated by monitoring tumor growth, development, and life span.
The in vitro eﬀects were measured through cell growth kinetics, cell proliferation, mitochondrial membrane potential disruption
assay, and light and scanning electron microscopy. All drug treatments extended the mean life span of the 4T1-inoculated tumor-
bearing mice; however, only tamoxifen and combination treatments statistically increased the life span when compared to untreated
mice. Although the most drug inhibitory eﬀect on cell multiplication was observed in the combination treatment, both anastrozole
and tamoxifen individually inhibited cell proliferation signiﬁcantly at most time periods in this mouse breast cancer cell line. The
mitochondrial membrane potential disruption assay demonstrated signiﬁcant increase in the percent of cells undergoing apoptosis
in all treatment groups. However, the combination treatment was the most eﬀective in inducing cell death via apoptosis. Light and
scanning electron microscopy of the treated cells revealed characteristics such as rounding, clumping, and shrinkage of the cells as
well as formation of cell surface blebbing and apoptotic bodies suggestive of cell death via apoptotic pathway.
INTRODUCTION
For the past twenty years, tamoxifen has been the
drug of choice for the treatment of advanced-stage estro-
gen receptor positive (ER-positive) breast cancers [1, 2].
This antibreast cancer drug is often successful in lim-
iting breast cancer growth initially, but continued use
of the drug was known to stimulate disease progression
[3, 4]. Because drug treatment with tamoxifen is not
ideal, other hormonal chemotherapies have been devel-
oped. Second-generation treatments were developed but
were overshadowed by the rapid success and develop-
ment of the third-generation aromatase inhibitors such as
anastrozole, letrozole, and vorozole [5]. The most pop-
ular of the aromatase inhibitors is anastrozole, or Arim-
idex, which is used to treat ER-positive breast cancers in
postmenopausal women. Anastrozole binds to aromatase
eliminating its estradiol synthesizing function, resulting
inadropinthecirculatinglevelofestrogen[6,7].In1995,
anastrozolewasoriginallyapprovedbytheFoodandDrug
Administration (FDA) as the ﬁrst nonsteroidal aromatase
inhibitor for the treatment of tamoxifen-resistant ER-
positive breast cancer [8, 9]. Later, in 2000, anastrozole
was approved for ﬁrst-line treatment of advanced ER-
positive breast cancer by the FDA [10, 11]. In June 2002,
the preliminary results of a massive anastrozole study
comparing its eﬀectiveness alone and in combination
with tamoxifen (ATAC) found that anastrozole alone was
statistically more eﬀective than either tamoxifen alone
or in combination with anastrozole in the treatment of
breast cancer in postmenopausal women [12]. In recent
studies, anastrozole was shown to shrink tumor size al-
lowing previously inoperable breast cancers to become
operable [13].
Studies aimed at comparing the eﬃcacies of anastro-
zole and tamoxifen in various breast cancer treatment set-
tings and stages have produced conﬂicting results. A mul-
ticenter randomized trial revealed that anastrozole was
more eﬀective than tamoxifen in slowing breast cancer
tumor progression in women diagnosed with advanced-
stage breast cancer [10]. In contrast, a similar multicenter
randomized trial conducted by Bonneterre et al [14]r e -
ported no signiﬁcant diﬀerence in tumor progression be-
tween women treated with anastrozole and those treated
with tamoxifen. Furthermore, information on the eﬀec-
tiveness of anastrozole, tamoxifen, and their combination
on nonmammalian breast cancer cells both in in vivo and
in vitro settings is limited. Consequently, future studies
evaluating the eﬃcacies of tamoxifen, anastrozole, and
the combination in various mammalian systems involv-
ing diﬀerent breast cancer cell types are needed in order
to evaluate the best strategy for the treatment of breast
cancers. To the best of our knowledge, no reports on the
eﬀects of treatments with anastrozole, tamoxifen, and the
combination on this mouse breast cancer cell line (4T1)
have been published.2005:1 (2005) Anastrozole, Tamoxifen, and Combination on Mouse Breast Cancer 11
The 4T1 cells grow as adherent epithelial type in
vitro, and are characterized as murine mammary carci-
noma cells (American Type Culture Collection (ATCC)
catalogue no. CRL-2539, 2004). When injected into
BALB/c mice, 4T1 cells rapidly multiply resulting in
highly metastatic tumors. Because these tumors closely
imitate human breast cancer, the 4T1 cell line serves as an
animal model for stage IV breast cancer [15]. In this in-
vestigation, we evaluated the eﬀectiveness of anastrozole,
tamoxifen, and the combination on 4T1 cells’ ability to
induce tumors in BALB/c female mice. Various parame-
ters such as tumor induction capability, tumor mass, and
mean life span were recorded to determine the drugs’ ef-
ﬁcacy on 4T1 cells. Additionally, the drugs’ eﬀects on 4T1
cell growth kinetics, proliferation, and morphology were
investigated. In order to determine the mechanisms of the
death of 4T1 cells exposed to individual and combina-
tion drug treatments, a mitochondrial membrane poten-
tial disruption assay and a scanning electron microscopy
(SEM) investigation were performed.
MATERIALS AND METHODS
Cellmaintenance
In vivo and in vitro studies were performed utiliz-
ing the 4T1 cell line. This cell line was supplied to this
laboratory by Dr. Robert Kurt (Lafayette College, Easton,
Pa). The cells were cultured in Dulbecco’s modiﬁed Ea-
gle’s medium (Gibco BRL, Rockville, Md) supplemented
with 10% fetal calf serum (Sigma Aldrich, St Louis, Mo)
(DME-10) and kept in a 37◦C humidiﬁed incubator with
7.5% CO2 in air. The 4T1 cells used in the tumor devel-
opment study were freshly harvested by Dr. Robert Kurt
from 4T1-induced tumors in BALB/c mice.
Mousemaintenance
Three-to-four-week-old female BALB/c mice were
purchased from Ace Animals (Boyerstown, Pa). The mice
were housed four or ﬁve to a cage, fed ad libitum, and ob-
served daily. The cages were kept in a climate-controlled
warm animal suite and cleaned weekly. Approval for this
studywasattainedfromtheLafayetteCollegeInstitutional
Animal Care and Use Committee (IACUC) and the mice
were handled and euthanized according to its guidelines.
Drugpreparation
Tamoxifen citrate ((Z)-1-(p-dimethylaminoethoxy-
phenyl)-1,2-diphenyl-1-butene) was purchased from
Sigma Aldrich (St. Louis, Mo). The tamoxifen citrate
powder was dissolved in a phosphate buﬀered saline
(PBS) solution to a concentration of 1000µg/mL and
stored at −20◦C; this served as a stock solution. The 4T1
cells utilized in the in vitro studies were treated with a
5µg/mL concentration of tamoxifen citrate. In the in vivo
study, each mouse was injected subcutaneously with 5µg
of tamoxifen citrate in 0.1mL of PBS. Injection protocols
are provided in the “tumor development study” section.
Arimidex, 1 mg anastrozole tablets, manufactured by
Astra Zeneca (London, England) were obtained through
the Bailey Health Center (Lafayette College, Easton, Pa)
from Bell’s Apothecary (Easton, Pa). The tablets were dis-
solved in PBS to a ﬁnal concentration of 500µg/mL stock
solution and stored at −20◦C. Cells for in vitro stud-
ies were treated with 30µg/mL or 50µg/mL of anastro-
zole, while mice in the in vivo study were injected as de-
scribed above with 50µg of anastrozole per mouse daily
during the treatment period. The combination of anas-
trozole (50µg/mL) and tamoxifen (5µg/mL) was used for
both in vitro and in vivo investigations.
Camptothecin, a known inducer of apoptosis [16],
was purchased in powder form from Sigma Aldrich (St.
Louis, Mo) and was dissolved in PBS to a ﬁnal concentra-
tion of 1000µg/mL. The agent was used as a positive con-
trol in the mitochondrial membrane potential disruption
study (3.5µg/mL).
Tumordevelopmentstudy
Seven-week-old female BALB/c mice were injected
subcutaneously with 105 4T1 cells suspended in 0.1mLof
PBS on the upper portion of the right hind thigh on day
zeroofthestudy.Theindividualorcombinationregimens
of each drug dissolved or suspended in 0.1mL PBS were
injected subcutaneously on the inside of either thigh ev-
ery48hourswitha25gaugesyringe.Eachmousereceived
14 doses of its designated drug over a 28 day period. Mice
in the untreated group were similarly given 14 doses of
0.1mL of PBS.
Thedayoftumorinductionwasrecorded.Tumorvol-
ume(tumor volume = length×width2×0.5)wasrecorded
twice per week following the equation utilized by Kotoh
et al and Ruddy and Majumdar in similar tumor devel-
opment studies [17, 18]. The mice were examined every
other day for maladies including rough coat appearance,
discoloration of skin, and swollen abdomen. Mice were
sacriﬁced approximately 1–2 days prior to their natural
death by cervical dislocation and life span was recorded.
After euthanization, the mice were dissected. The pri-
mary tumor, liver, and spleen were removed, studied, and
weighed.
Cellkineticsstudy
Fifty thousand 4T1 cells were seeded in each well of
a six-well plate in 4mL of DME-10 and treated with ta-
moxifen citrate, anastrozole, and the combination of the
two drugs. The 4T1 cells were harvested using a 0.25%
buﬀered trypsin solution (Gibco BRL, Rockville, Md),
and viable cells were counted using the trypan blue ex-
clusion method at 24-hour intervals for ﬁve days.
Cellproliferationstudy
Ten thousand exponentially growing 4T1 cells were
added to each well of a 96-well plate as suggested by the
Quick Cell Proliferation Assay Protocol obtained from
Biovision (Quick Cell Proliferation Assay Kit, Mountain12 J. M. Xanthopoulos et al 2005:1 (2005)
Table 1. Summarized results of the tumor development study. Female BALB/c mice were inoculated with 10000 4T1 cells subcu-
taneously in the right hind thigh and treated with anastrozole, tamoxifen, the combination, or the untreated phosphate buﬀered
solution.
Mean tumor detection day ± SEM Mean life span ± SEM Mean tumor mass at death ± SEM
Untreated 10.8 ±1.12 4 .8 ±1.70 .841 ±0.325
Anastrozole 11 ±0.72 6 .9 ±1.61 .252 ±0.308
Tamoxifen 9.5 ±0.73 1 ±1.1∗ 1.840 ±0.173∗
Anastrozole +
Tamoxifen
10.5±0.7 29 ±1.6∗ 1.413 ±0.215
∗Statistical diﬀerence from the untreated control group (P ≤ .05), as determined by the Student t test.
Statistical diﬀerence from the anastrozole-treated group (P ≤ .05), as determined by the Student t test.
View, Calif). Anastrozole, tamoxifen, or the combination
of the two drugs was added to the cells in each well. A
blank was prepared by adding only culture media to a row
of wells. Twenty-four hours later, each well was supplied
with10µL of a mixture of the tetrazolium salt WST-1 and
an electrocoupling solution. The plate was incubated for
three hours in a 37◦C humidiﬁed incubator with 7.5%
CO2 in air. Mitochondrial dehydrogenases found in vi-
able cells converted WST-1 to a formazan dye during this
incubation period. Dye formation, indicative of cell via-
bility, was quantiﬁed by measuring absorbency at 450nm
with an EL312E Automated Microplate Reader (Bio-TeK
instruments, Winooski, Vt). After 24 hours of treatment,
the cells were studied under an inverted Olympus mi-
croscope (Melville, NY) at 100× magniﬁcation and pho-
tographed digitally using a MX-700 fujiﬁlm digital cam-
era (Tokyo, Japan).
Mitochondrialmembranepotential(∆ψ)
disruptionassay
The 4T1 cells were grown on square sterile cover-
slips in 60 × 15mm tissue culture dishes with 2mL
of DME-10. After 24 hours the cells were treated with
tamoxifen citrate, anastrozole, or a combination of ta-
moxifen citrate and anastrozole in varied concentrations
as speciﬁed above for 24, 48, and 72 hours. Camptothecin
(3.5µg/mL), a known apoptotic inducer, was used as a
positive control [16]. Following the Trevigen protocol,
using the DesPsipher Mitochondrial Membrane Potential
Disruption Kit (Trevigen, Inc, Gaithersburg, Md), the
incubating solution was prepared which contained 1X
reaction buﬀer, stabilizing solution, and the DePsipher
solution. The adherent cells on coverslips were incubated
for 30 minutes in the above solution in a humidiﬁed
incubator at 37◦Ci n7 .5% CO2 in air. The slides were
examined under a ﬂuorescence microscope (Bausch
and Lomb, Rochester, NY) with a dual ﬁlter set of
FITC and rhodamine for detection of mitochondrial
membrane potential disruption. The normal mem-
brane potential of mitochondria was indicated when
the DePsipher lipophilic cation (5,5 ,6,6 ,tetrachloro-
1,1 ,3,3 ,tetraethylbenzimidazolyl carbocyanin) aggre-
gated on the membrane forming a red-orange ﬂuorescent
compound. However, if the membrane polarization is
disrupted, the cation cannot access the mitochondrial
transmembrane space and the cells remain green. This
is an early indication of apoptosis. Approximately 300
cells per treatment and time interval were examined.
Photographs were taken using an Olympus C-35 camera
(Tokyo, Japan) with ISO 1600 speed ﬁlm utilizing a
30-second time exposure.
Scanningelectronmicroscopy
The 4T1 cells were grown on sterile circular coverslips
in small culture dishes in 3mL of DME-10 with either
tamoxifen citrate, anastrozole, or the combination of the
twodrugs.After48hoursofdrugtreatment,thecellswere
ﬁxed in 2% glutaraldehyde, post ﬁxed in a 1% osmium
tetroxide solution, dehydrated in an ascending series of
ethanol,andcriticallypointdried(PolaronE3000,Moun-
tain View, Calif). The cells were sputter-coated with gold
palladium using a Cressington 108 auto sputter coater
(Cranberry Township, Pa) and examined with an ISI Su-
perIIIAscanningelectronmicroscope.Photographswere
taken with B52 and B55 Polaroid pan ﬁlms as well as the
Printerface computer program.
Statisticalanalysis
Statistical analyses pertaining to toxicological experi-
ments were performed according to the statistical meth-
ods recommended by Gad and Weil [19]. These included
Bartlett’s homogeneity of variance, unpaired Student’s t
test, F test, Tukey’s test, chi-square test, and Fisher’s exact
test[19,20].MicrosoftExcelwasusedtocompiledataand
to create corresponding graphs and tables.
RESULTS
Tumordevelopmentstudy
Table 1 summarizes the results of the tumor develop-
ment study. Mice were sacriﬁced approximately 2–3 days
prior to natural death by cervical dislocation. Matting
and thinning of fur, discoloration of skin, substantial tu-
morsizecausingparalysis,largeswollenabdomens,frailty
or thinning, and overall lethargy were the characteris-
tics used as indicators of near death. The mean life span2005:1 (2005) Anastrozole, Tamoxifen, and Combination on Mouse Breast Cancer 13
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Figure 1. Mean life spans of 4T1-inoculated mice. Stars indi-
cate statistical diﬀerence from the untreated group (P ≤ .05), as
determined by the Student t test. Bars represent ± SEM.
of each treatment group was calculated. Utilizing an un-
pairedunequalvarianceStudentt test,themeanlifespans
of the tamoxifen-treated mice were found to be signiﬁ-
cantly longer than the mean life spans of the mice in the
anastrozole treated and untreated groups (see Figure 1).
The combination treatment also extended the life spans
of the mice which were found to be statistically diﬀer-
ent from the untreated group (P<. 05) but not from
either the anastrozole- or tamoxifen-treated groups (see
Table 1). Tamoxifen appeared to be most eﬀective in the
trial. Tumor volume was measured throughout the ex-
periment but no statistical signiﬁcance was found on any
day across the treatment groups. After death the tumors
were removed and studied. Mean tumor mass at death
was calculated and the average tumor mass of tamoxifen-
treated mice was found to be signiﬁcantly larger than that
of the untreated group by the Student t test (see Table 1).
Those mice with both swollen abdomens and discolored
skin, sacriﬁced early due to their very ill appearance, had
smaller tumors. Upon dissection, the abdomens of these
mice were found to be ﬁlled with a dark brown ﬂuid.
When the ﬂuid was removed from its source and injected
into BALB/c female mice, 100% tumor formation oc-
curred at the site of injection within 14 days.
Because of the high metastatic characteristic of 4T1
cells, the spleens and livers of 4T1-inoculated mice were
also examined post mortem for evidence of secondary
cancer development. Spleen enlargement was observed in
4T1-inoculated mice that did not receive the drug (see
Figure 2). In the untreated group, the spleen mass was as
much as ten times larger than that of a cancer-free mouse.
Although there was no statistical diﬀerence in the aver-
ages of spleen size at death across the treatment groups,
mice sacriﬁced from each group on day 28 of the experi-
ment exhibited clear size and mass diﬀerences. The largest
spleen size and mass were detected in the 4T1-inoculated
mouse that received no drug treatment. The spleen size
and mass increased over the remaining treatments of
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Figure 2. Spleen masses of female BALB/c mice on day 28 of the
experiment. All mice except the normal (negative control) were
inoculated with 4T1 cells 28 days prior to spleen removal and
treated with either PBS, anastrozole, tamoxifen, or the combi-
nation.
anastrozole-, tamoxifen-, and combination-treated mice,
respectively. Cancerous nodules often appeared in the liv-
ers of 4T1-infected mice although no signiﬁcant variation
in mean liver mass at death was found across the treat-
mentgroups.Furthermore,themeantumordetectionday
across the treatment groups revealed no statistical diﬀer-
ence (see Table 1).
Cellmultiplicationstudy
Cell growth inhibition of 4T1 in presence of anas-
trozole was in general concentration-dependent. The
50µg/mL anastrozole treatment statistically reduced vi-
able cell number compared to the untreated control at
all time periods, while the 30µg/mL anastrozole treat-
ment diﬀered signiﬁcantly from the untreated cells only
at 96 and 120 hours (see Figure 3). When 30µg/mL and
50µg/mL of anastrozole treatments were compared, a sta-
tistical diﬀerence in the number of viable 4T1 cells was
detected at the 72-hour time period.
Both the tamoxifen (5µg/mL) and the combination
treatment (anastrozole 50µg/mL and tamoxifen 5µg/mL)
inhibited 4T1 cell growth (see Figure 4). The number of
viable cells in the tamoxifen- and combination-treatment
groups was statistically fewer than in the untreated cells at
48, 72, 96, and 120 hour time periods. The combination
treatment was found to be a more eﬀective inhibitor of
4T1 viability than the tamoxifen treatment at all time pe-
riods. At all time periods, the number of viable 4T1 cells
treated with the combination was less than the number of
cellsusedintheinitiationofthestudy.Whencomparedto
anastrozole (50µg/mL), the combination treatment was
found to exert a greater inhibitory eﬀect on cell multipli-
cation; anastrozole alone (50µg/mL), however, was more
eﬀective than tamoxifen in reducing 4T1 cell viability fol-
lowing 24 hours of drug treatment.14 J. M. Xanthopoulos et al 2005:1 (2005)
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Figure 3. Cell growth kinetics of untreated and anastrozole-
treated 4T1 (30 or 50µg/mL). Stars indicate a statistical dif-
ference in number of viable cells from the untreated groups
(P ≤ .05), as determined by the Student t test. A diamond in-
dicates a statistical diﬀerence between the two anastrozole con-
centration groups. Bars represent ± SEM.
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Figure 4. Growth kinetics of untreated, tamoxifen-treated
(5µg/mL), and combination-treated (anastrozole 50µg/mL and
tamoxifen 5µg/mL) 4T1 cells. Combination treatment drasti-
cally reduced cell number throughout the study period. Stars
indicate statistical diﬀerence in number of viable cells from the
untreated groups (P ≤ .05). Bars represent ± SEM.
Cellproliferation
In order to determine 4T1 cell viability following 24
hours of drug treatment, a WST-1 solution was added to
each well and converted to a quantiﬁable yellow dye by
mitochondrialdehydrogenasespresentinviablecells,thus
serving as an indirect gauge of 4T1 viability. (See “materi-
als and methods.”) A microplate reader was used to mea-
suretheabsorbencyofthesolutionineachwell.Statistical
analysis of the absorbencies revealed a decrease in 4T1 cell
viability following 24 hour anastrozole and combination
drug treatments when compared to untreated cells. No
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Figure 5. Cell proliferation assay results utilizing absorbency
(450nm) as a measure of viability in cells untreated or treated
with anastrozole (50µg/mL), tamoxifen (5µg/mL), or the com-
bination (anastrozole and tamoxifen). Stars indicate a statistical
diﬀerence from the untreated groups (P ≤ .05). Diamonds indi-
cate a statistical diﬀerence from the tamoxifen group (P ≤ .05).
Bars represent ± SEM.
statistical diﬀerence was detected between the anastrozole
and combination treatments (see Figure 5). Additionally,
bothanastrozole-andcombination-treatmentgroupshad
signiﬁcantly less viable cells than the tamoxifen-treated
group.
Lightmicroscopy
Untreated samples exhibited the cell’s normal mor-
phology (see Figure 6a). The adherent cells are either
rounded or are stretched to an elongated shape by the
presence of long cytoplasmic processes called lamellipo-
dia. In contrast, most cells in the drug-treated groups
appeared rounded and irregular in shape and exhibited
clumping as well as destruction of cell membrane, cell ly-
sis, and cell fragmentation (see Figures 6b, 6c,a n d6d). In
addition to the heterogeneous appearance, there was also
a decrease in cell number in all treatment groups; how-
ever, this eﬀect was more pronounced in the tamoxifen
and combination groups.
Mitochondrialmembranepotentialdisruption
In most cases treated cells appeared rounded and
green under the ﬂuorescence microscope due to the mi-
tochondrial membrane disruption in the DePsipher assay
pointing to an early sign of apoptosis. In contrast, 68%–
72% of untreatedcellsshowed red-orange coloration dur-
ing the 72 hour study period indicating nondisruption of
the mitochondrial membrane (see Figure 7). Chi-square
analysis demonstrated signiﬁcant diﬀerences among the
untreated and treated groups, signifying that these two
drugs alone and in combination elicited a higher inci-
dence of apoptosis. As expected, the combination treat-
ment was found to be the most potent in inducing
cell death possibly via apoptosis which generally paral-
leled camptothecin treatment. The incidence of cell death
observed between the combination and tamoxifen was2005:1 (2005) Anastrozole, Tamoxifen, and Combination on Mouse Breast Cancer 15
(a) (b)
(c) (d)
Figure 6. Light microscopy images of 4T1 cells (a) untreated
or treated for 24 hours with (b) anastrozole (50µg/mL), (c) ta-
moxifen citrate (5µg/mL), or (d) the combination of the two
drugs.Untreated4T1cellsareeitherroundedorﬂattened.Drug-
treated cells appear mostly rounded in shape, clumped, and dis-
rupted (×100).
statistically diﬀerent at 72 hours. Tamoxifen compared to
anastrozole appeared more eﬀective in inducing death in
4T1 mouse breast cancer cells (see Figure 7).
Scanningelectronmicroscopy
The two drugs alone or in combination induced sur-
face ultrastructural changes in 4T1 cells (see Figure 8).
Untreated4T1cellswerebothsphericalandﬂattenedwith
long cytoplasmic processes (see Figure 8a). The untreated
groups exhibited certain frequencies of clumping nor-
mally after 48 hours; this is depicted at higher magniﬁca-
tion in Figure 8b. The cultures exposed to anastrozole for
24 hours showed rounding and clumping as well as thin-
ning of lamellipodia (see Figure 8c). Various surface ab-
normalities including apoptotic bodies and blebs as well
as lysed cells were discerned at higher magniﬁcation (see
Figure 8d).
Signiﬁcantly fewer cells and more cell clumping were
observed in the tamoxifen-treated group as compared to
untreated cells viewed at the same magniﬁcation. The
tamoxifen-treated cells were irregular in shape with lit-
tle or no lamellipodia. Formation of apoptotic bodies,
membrane blebbing, and holes in the cell membrane was
evident (see Figure 8e). Exposure to the combination of
anastrozole and tamoxifen resulted in the most drastic
changesincellnumbersandultrastructure(seeFigure 8f).
Membrane blebs, holes, and apoptotic bodies as well as
lysed and irregularly shaped cell clumps of various sizes
were detected.
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Figure 7. Incidence of apoptotic 4T1 cells as detected through
mitochondrial membrane potential disruption assay. Stars indi-
cate statistical diﬀerence (chi-square) from the untreated group
(P<. 05). Statistical diﬀerence among the time periods is
indicated by crosses. Diamonds demonstrate statistical diﬀer-
ence between tamoxifen (5µg/mL) and anastrozole (50µg/mL),
camptothecin (3.5µg/mL), and the combination (50+5µg/mL)
whereas squares indicate statistical diﬀerence among anastro-
zole, camptothecin, and the combination. Bars indicate ± 1
SEM.
DISCUSSION
Since the 1970, tamoxifen has been used to treat
hormone-sensitive breast cancers. However, studies have
shown that prolonged treatment with tamoxifen may
yield tamoxifen-resistant breast cancer [3]. In 1995, anas-
trozole, a third-generation nonsteroidal inhibitor, was in-
troduced and later approved to treat both early- and
advanced-stage ER-positive breast cancers [10, 21]. Still,
eﬃcacy data comparing the two drugs on various breast
cancer types are incomplete [22]. This study was initiated
to investigate the eﬀects of the two drugs alone and in
combination on mouse breast cancer cells (4T1 cell line)
in inducing tumor in BALB/c female mice and the drugs’
role in 4T1 cell growth kinetics, proliferation, and mor-
phologyandtodecipherthemechanismsofdrug-induced
cell death.
This study has shown that treatment with tamoxifen
signiﬁcantly increased the life spans of 4T1-inoculated
mice when compared to anastrozole-treated or-untreated
mice. Similarly, the combination treatment with anastro-
zole and tamoxifen also lengthened the lives of mice when
compared to untreated mice. There was no signiﬁcant
diﬀerence between the tamoxifen and combination
groups even though the mice in the combination groups
received full doses of both drugs. Therefore, anastrozole
did not appear to be eﬀective alone or in combination in
this in vivo mouse study.16 J. M. Xanthopoulos et al 2005:1 (2005)
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Figure 8. Scanning electron micrographs of untreated and
24-hour-treated 4T1 cells with anastrozole (50µg/mL), tamox-
ifen citrate (5µg/mL), and the combination of the two drugs
(50µg/mL and 5µg/mL). (a) Characteristics of untreated 24
hour culture showing rounded and ﬂattened cells. (b) Normal
surface characteristics of untreated clumped cells shown at 48
hour. (c) Twenty-four-hour anastrozole-treated 4T1 cells show-
ing various surface abnormalities (arrows). (d) Enlarged view of
24-hour anastrozole-treated 4T1 cells depicting apoptotic bod-
ies(a),blebs(b),andlysedcells(l).(e)Tamoxifen-treatedcellsat
24 hour depicting irregularly shaped cells with apoptotic bodies
(a) and holes (h). (f) Anastrozole- and tamoxifen-treated cells.
The irregularly shaped cells depict many surface ultrastructural
changes including blebs and membrane holes.
Preliminaryreportsfromlarge-scalestudieslikeATAC
reported that anastrozole’s eﬃcacy in humans was supe-
rior to that of tamoxifen in the adjuvant setting [12]. A
study conducted by Lu et al [23] found that treatment
with letrozole, another aromatase inhibitor, was more ef-
fective in suppressing human tumor growth in nude mice
than the tamoxifen treatment or the combination treat-
ment of letrozole and tamoxifen. In a similar study con-
ducted by Long et al [24], letrozole again demonstrated
superior eﬃcacy when compared to tamoxifen in terms of
time for tumor progression in mice. However, the female
BALB/c mice used in our study contained both ovaries
unlike the mice utilized in the studies conducted by Lu
et al [23] and Long et al [24]. Since ovaries are the main
siteofestrogenproductioninpremenopausalwomen,itis
reasonable to infer that estrogen levels in these mice were
signiﬁcantly higher than those in ovariectomized mice.
Premenopausal women have estrogen levels of approxi-
mately 379pcg/mL, while postmenopausal women have
estrogen concentrations around 83pcg/mL [25]. There-
fore, even if anastrozole is blocking estrogen produc-
tion by inhibiting aromatase, signiﬁcant levels of estrogen
wouldstillbepresentandthusestrogen-stimulatedtumor
progression could proceed.
Tamoxifen works by binding directly to the estrogen
receptor, forming an estrogen receptor complex. Unlike
anastrozole, tamoxifen’s mechanism of action is indepen-
dent of circulating levels of estrogen. In fact, tamoxifen is
eﬀective against ER-positive breast cancer found in pre-
menopausal women [2]. Therefore, even if estrogen lev-
els in our in vivo study are more similar to those in pre-
menopausal women than those found in postmenopausal
women, we would still expect the drug to elicit an in-
hibitory eﬀect on 4T1 mouse breast cancer growth. This
eﬀectwasdemonstratedinthepresentinvestigationbythe
observed increase in mouse life span treated with tamox-
ifen and the combination.
Conversely, no statistical signiﬁcance was observed in
tumor induction time, calculated average tumor volume,
or liver and spleen mass at death in any of the treatment
groupswhencomparedtountreatedmice.Onefactorthat
may have contributed to the lack of statistical signiﬁcance
in these areas was probably due to the high number of
cells used to induce the tumor. In a subsequent study per-
formed in our laboratory, female BALB/c mice were in-
jected with 1000 and 5000 4T1 cells and tumor develop-
ment was studied. All mice developed palpable tumors by
day 18 of the study. The high metastatic ability of the 4T1
cell line was demonstrated in a study conducted by Pu-
laski et al [26]. These investigators noted that 4T1 metas-
tasizes to the lungs, livers, and brains of inoculated mice
as early as two to three weeks after a 7000 4T1 cell inoc-
ulation. Therefore, the initial injection of 10000 4T1 cells
used in our study was most likely too strong in terms of
tumor development for diﬀerential tumor volume obser-
vations for the treatment groups. However, the diﬀerence
in spleen size noted on day 28 may be an indication of
diﬀerent degrees of 4T1 metastasis occurring across the
treatment groups. Tamoxifen treatment may have played
aroleinprolongingthelifeoftheBALB/cmicebyslowing
down the metastasis to other areas of the body.
Tumor, spleen, and liver mass at death did not serve
as good indicators of drug eﬃcacy because of the diﬀer-
ential survival time observed for the mice across the treat-
ment groups. Because mice in the tamoxifen treatment
group typically lived longer than mice in the groups that
did not receive any of the drugs, these mice had a longer2005:1 (2005) Anastrozole, Tamoxifen, and Combination on Mouse Breast Cancer 17
period of time for primary tumor and spleen enlarge-
ment. This could explain the signiﬁcant diﬀerence in tu-
mor mass at death observed between tamoxifen-treated
and- untreated mice.
Several mice that were near death early in the study
were characterized by a swollen abdomen. These mice
suﬀered from ascites, a condition characterized by ex-
cess ﬂuid in the abdomen. In a 2002 study, Hasumi et
al [27] reported that advanced ovarian cancer often in-
vades the peritoneal cavity resulting in ascites that some-
times contained malignant cells. The development of as-
cites was shown to inversely aﬀect survival time in hu-
mansbyRoszkowskietal[28].Miceobservedwithabnor-
mally swollen abdomens in this study were determined to
be close to natural death and were sacriﬁced. After dissec-
tion, ﬂuid from the abdomen was collected and injected
into three BALB/c mice. Tumor formation in all the three
mice indicated that the ascites condition occurred as a re-
sult of the 4T1 metastasis.
Thecellkineticsstudyconductedinvitrorevealedthat
anastrozole, tamoxifen, and the combination of the two
drugs elicited a growth inhibitory response in the 4T1
mousemammarycarcinomacellline.The50µg/mLanas-
trozole and combination treatments signiﬁcantly reduced
cell viability in each study period when compared to un-
treated cells, while tamoxifen-treated cells did not diﬀer
signiﬁcantly from untreated cells after 24 hours of drug
treatment. These results agree with the quantiﬁed cell
proliferation results. However, in the qualitative analy-
sis, utilizing both light and scanning electron microscopy,
tamoxifen and combination treatments appeared to be
moredamagingthananastrozolealoneinaltering4T1cell
morphology. Furthermore, fewer 4T1 cells were observed
per ﬁeld of view in the tamoxifen and combination treat-
ments when compared to anastrozole or untreated cells.
Compared to anastrozole, the cells treated with tamox-
ifen showed more cell damages such as lysis, irregular cell
shapes, blebbing, and prevalence of membrane holes after
24 hours of drug treatment.
A possible explanation for the apparent discrepancy
between quantitative and qualitative data might be due to
the disruption of cell adhesion leading to detachment of
cells from the substratum. In 2002, Palencia et al [29], in
their study on thalidomide, suggested that although the
agent was not cytotoxic to neoplastic cells, it might have
inhibited tumor growth by blocking cell-surface adhesion
receptors. A similar mechanism may be in operation with
tamoxifen. Tamoxifen might have altered the cell’s abil-
ity to adhere to the cell surface releasing it into the me-
dia without initially killing the cell. In a study conducted
byDamiano,integrincelladhesionmoleculeswereshown
to protect myeloma cells from drug-induced apoptosis.
They suggested that integrin antagonists capable of iso-
lating tumor cells would be eﬀective in cancer treatment
by sensitizing the cell and making the cell more prone
to apoptosis [30]. Tamoxifen’s reduction of cell adhesion
demonstratedinvitromaybeindicativeofinterruptionof
normal integrin reception. The tamoxifen-induced loss of
cell adhesion combined with anastrozole treatment in the
cell multiplication study may explain the signiﬁcant de-
crease in cell viability observed when the two drugs were
administered in combination compared to either agent
alone. The adverse eﬀects of the drugs on proteins that
are required to maintain cell structures such as interme-
diate ﬁlaments, actin, gelsolin, and laminin might have
led to changes in cell shape, cell fragmentations, as well
as in formation of cell membrane blebbing and apoptotic
bodies [31].
The mitochondrial membrane potential disruption
assay was used to detect one of intracellular changes oc-
curring in the activation phase of apoptosis in 4T1 cells
[32, 33]. Apoptosis, or programmed cell death, is a mech-
anism of cell suicide which can be divided into two ma-
jor phases: the activation and execution phases [31]. A
variety of chemotherapeutic drugs initiate apoptosis in
tumor cells leading to the regression of a cancerous tu-
mor [32]. In this study, all treatment groups exhibited
a higher incidence of apoptosis compared to untreated
cells. Estrogen is a known apoptotic inhibitor [34]. It is
possible that both anastrozole and tamoxifen directed the
cellstowardapoptosisbyinterferingwithvariousestrogen
signaling events. In their study, Davis and Majumdar re-
portedthatraloxifene,aselectiveestrogenreceptormodu-
lator with anti-breast-cancer potential, showed high inci-
dences of apoptosis through disruption of the mitochon-
drial membrane [32]. In our study, the highest incidence
of apoptosis was seen in the combination treatment of ta-
moxifen citrate and anastrozole. However, at 72 hours no
signiﬁcant diﬀerence was detected between combination-
and tamoxifen-treated cells due to an extremely high inci-
dence of cell loss. Since mitochondrial membrane poten-
tial disruption was observed in all treatment groups, the
results of this assay suggest that the initial mechanism of
celldeathelicitedbyanastrozole,tamoxifen,andthecom-
bination was triggered via apoptotic pathway.
Surface ultrastructural characteristics detected in the
SEM study also suggest that apoptosis may be the mecha-
nism of drug-induced cell death at the initial treatment
period. Speciﬁc morphological alteration identiﬁed in
the micrographs of drug-treated cells included apoptotic
bodyformation,cellmembraneblebbing,andthinningof
lamellipodia; these are characteristics which are indicative
of apoptosis [35, 36]. Perry et al used transmission elec-
tron microscopy to conclude that apoptosis was induced
inhumanbreastcancercellsfollowingexposuretotamox-
ifen [37].
Eﬃcacies of anastrozole, tamoxifen, and the com-
bination treatments were examined in in vitro and in
vivo settings in the mouse model. While in vitro experi-
mentsshowedasigniﬁcantgrowthinhibitoryeﬀectin4T1
mouse breast cancer cells exposed to all treatments, the in
vivo tumor development study indicated that tamoxifen
and the combination treatments extended the survival
time for BALB/c female mice. Although the survivability
was increased by several days in anastrozole-treated mice,
the diﬀerence in life span between the anastrozole-treated18 J. M. Xanthopoulos et al 2005:1 (2005)
and untreated 4T1-inoculated mice was not statistically
signiﬁcant. In vitro assay procedures might suggest that
both the drugs and their combination treatments ex-
tended cell death via an apoptotic pathway.
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